All Stories

  1. Rethinking HIV antibody testing in children aged 18-24 months in the OPPTIM study conducted in Johannesburg, South Africa 2018-2021

    Article • Diagnostic Microbiology and Infectious Disease, November 2026, Elsevier

    Lee Fairlie

  2. Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine

    Article • Open Forum Infectious Diseases, June 2026, Oxford University Press (OUP)

    Lee Fairlie

  3. Letter Reply to “Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis”

    Article • The Journal of Infectious Diseases, May 2026, Oxford University Press (OUP)

    Lee Fairlie

  4. Rethinking HIV antibody testing in children aged 18-24 months in the OPPTIM study conducted in Johannesburg, South Africa 2018-2021

    Article • January 2026, Elsevier

    Lee Fairlie

  5. Health system and household costs of preventive treatment delivery for children exposed to multidrug-resistant tuberculosis in South Africa

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  6. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s

    Article • The Journal of Infectious Diseases, October 2025, Oxford University Press (OUP)

    Lee Fairlie

  7. Clot twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS

    Article • South African Medical Journal, September 2025, Health and Medical Publishing Group

    Lee Fairlie

  8. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial

    Article • The Lancet HIV, August 2025, Elsevier

    Lee Fairlie

  9. Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis

    Article • Open Forum Infectious Diseases, July 2025, Oxford University Press (OUP)

    Lee Fairlie

  10. Characterizing the HIV care continuum among children and adolescents with HIV in eastern and southern Africa in the era of “Universal Test and Treat”: A systematic review and meta‐analysis

    Article • Journal of the International AIDS Society, June 2025, Wiley

    Lee Fairlie

  11. Bone Mineral Content, Growth, and Renal Health of Infants With Perinatal Exposure to Maternal Dolutegravir Versus Efavirenz and Tenofovir Disoproxil Fumarate Versus Tenofovir Alafenamide: The Randomized IMPAACT 2010 (VESTED) Trial

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, June 2025, Wolters Kluwer Health

    Lee Fairlie

  12. Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial

    Article • Clinical Infectious Diseases, May 2025, Oxford University Press (OUP)

    Lee Fairlie

  13. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2025, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  14. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s

    Article • Clinical Pharmacokinetics, March 2025, Springer Science + Business Media

    Lee Fairlie

  15. Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment

    Article • IJTLD OPEN, March 2025, International Union Against Tuberculosis and Lung Disease

    Lee Fairlie

  16. Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective

    Article • The Pediatric Infectious Disease Journal, February 2025, Wolters Kluwer Health

    Lee Fairlie

  17. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

    Article • The Lancet Child & Adolescent Health, February 2025, Elsevier

    Dr. Bakyt Bolotbekovich Myrzaliev, Lee Fairlie

  18. The need to avert emergent resistance to dolutegravir in children and adolescents with HIV

    Article • AIDS, January 2025, Wolters Kluwer Health

    Lee Fairlie

  19. Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

    Article • Human Vaccines & Immunotherapeutics, January 2025, Taylor & Francis

    Lee Fairlie

  20. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis

    Article • NEJM Evidence, January 2025, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  21. Burden of Lassa fever disease in pregnant women and children and options for prevention

    Article • Vaccine, January 2025, Elsevier

    Lee Fairlie

  22. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2024, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  23. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 i...

    Article • Human Vaccines & Immunotherapeutics, December 2024, Taylor & Francis

    Lee Fairlie

  24. Measles–Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations

    Article • Vaccines, November 2024, MDPI AG

    Lee Fairlie

  25. South African Parents’ and Grandparents’ Perspectives on the Acceptability of Implant Delivery of Treatment to Young Children with HIV

    Article • AIDS and Behavior, October 2024, Springer Science + Business Media

    Lee Fairlie

  26. Brief Report: Subsequent Pregnancies in the IMPAACT 2010/VESTED Trial: High Rate of Adverse Outcomes in Women Living With HIV

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2024, Wolters Kluwer Health

    Lee Fairlie

  27. Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2024, Wolters Kluwer Health

    Lee Fairlie

  28. Brief Report: Characterizing HIV Drug Resistance in Cases of Vertical Transmission in the VESTED Randomized Antiretroviral Treatment Trial

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, August 2024, Wolters Kluwer Health

    Lee Fairlie

  29. Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe

    Article • AIDS and Behavior, July 2024, Springer Science + Business Media

    Lee Fairlie

  30. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants

    Article • The Journal of Infectious Diseases, June 2024, Oxford University Press (OUP)

    Lee Fairlie

  31. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    Article • PLOS Global Public Health, April 2024, PLOS

    Lee Fairlie

  32. Assessment of weight gain in adult patients living with HIV receiving first‐line dolutegravir‐based or efavirenz‐based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study

    Article • HIV Medicine, March 2024, Wiley

    Lee Fairlie

  33. Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial

    Article • AIDS, March 2024, Wolters Kluwer Health

    Lee Fairlie

  34. Clot Twist – D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS

    Article • February 2024, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  35. Obstetric and neonatal outcomes in South Africa

    Article • Vaccine, February 2024, Elsevier

    Lee Fairlie

  36. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens

    Article • Open Forum Infectious Diseases, January 2024, Oxford University Press (OUP)

    Lee Fairlie

  37. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum

    Article • Clinical Infectious Diseases, January 2024, Oxford University Press (OUP)

    Lee Fairlie

  38. DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, January 2024, Wolters Kluwer Health

    Lee Fairlie

  39. More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2023, Wolters Kluwer Health

    Lee Fairlie

  40. Translating the consent form is the tip of the iceberg: using cognitive interviews to assess the barriers to informed consent in South African health facilities

    Article • Sexual and Reproductive Health Matters, December 2023, Taylor & Francis

    Lee Fairlie

  41. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    Article • November 2023, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  42. Preferences for onward health data use in the electronic age among maternity patients and providers in South Africa: a qualitative study

    Article • Sexual and Reproductive Health Matters, November 2023, Taylor & Francis

    Lee Fairlie

  43. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy

    Article • AIDS and Behavior, November 2023, Springer Science + Business Media

    Lee Fairlie

  44. Safety surveillance for PrEP in pregnant and breastfeeding women

    Article • Frontiers in Reproductive Health, September 2023, Frontiers

    Lee Fairlie

  45. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

    Article • Clinical Pharmacokinetics, August 2023, Springer Science + Business Media

    Lee Fairlie

  46. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2023, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  47. The burden, prevention and care of infants and children with congenital anomalies in sub-Saharan Africa: A scoping review

    Article • PLOS Global Public Health, June 2023, PLOS

    Lee Fairlie

  48. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19

    Article • Nature Immunology, June 2023, Springer Science + Business Media

    Lee Fairlie

  49. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

    Article • The Lancet HIV, June 2023, Elsevier

    Lee Fairlie

  50. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

    Article • Vaccine, May 2023, Elsevier

    Lee Fairlie

  51. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

    Article • The Lancet Infectious Diseases, March 2023, Elsevier

    Lee Fairlie

  52. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19

    Article • Viruses, February 2023, MDPI AG

    Lee Fairlie

  53. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

    Article • Scientific Reports, January 2023, Springer Science + Business Media

    Lee Fairlie

  54. High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa

    Article • International Journal of Infectious Diseases, December 2022, Elsevier

    Lee Fairlie

  55. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

    Article • October 2022, Research Square

    Lee Fairlie

  56. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa

    Article • AIDS, October 2022, Wolters Kluwer Health

    Lee Fairlie

  57. Acceptability of Implants for HIV Treatment in Young Children: Perspectives of Health Care Providers in Johannesburg, South Africa

    Article • AIDS Patient Care and STDs, October 2022, Mary Ann Liebert Inc

    Lee Fairlie

  58. Ambient temperature during pregnancy and risk of maternal hypertensive disorders: A time-to-event study in Johannesburg, South Africa

    Article • Environmental Research, September 2022, Elsevier

    Lee Fairlie

  59. Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from Africa

    Article • Frontiers in Pediatrics, August 2022, Frontiers

    Lee Fairlie

  60. HIV treatment success in children and adolescents with HIV

    Article • The Lancet HIV, August 2022, Elsevier

    Lee Fairlie

  61. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

    Article • BMJ Global Health, August 2022, BMJ

    Lee Fairlie

  62. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

    Article • BMC Infectious Diseases, July 2022, Springer Science + Business Media

    Lee Fairlie

  63. Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern

    Article • July 2022, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  64. Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

    Article • July 2022, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  65. Approaches to accelerating the study of new antiretrovirals in pregnancy

    Article • Journal of the International AIDS Society, July 2022, Wiley

    Lee Fairlie

  66. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

    Article • The Lancet HIV, May 2022, Elsevier

    Lee Fairlie

  67. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

    Article • February 2022, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  68. Combination HIV prevention reduces orphanhood in Uganda

    Article • The Lancet HIV, January 2022, Elsevier

    Lee Fairlie

  69. A public health approach to drug use crucial to ending AIDS

    Article • The Lancet HIV, January 2022, Elsevier

    Lee Fairlie

  70. Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  71. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir ...

    Article • AIDS, December 2021, Wolters Kluwer Health

    Lee Fairlie

  72. Pooled Prevalence of Adverse Pregnancy and Neonatal Outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results From a Systematic Review and Meta-Analyses to Inform Trials of Novel HIV Prevention Interventions During Pregnancy

    Article • Frontiers in Reproductive Health, November 2021, Frontiers

    Lee Fairlie

  73. Challenges in recruiting children to a multidrug-resistant TB prevention trial

    Article • The International Journal of Tuberculosis and Lung Disease, October 2021, International Union Against Tuberculosis and Lung Disease

    Lee Fairlie

  74. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

    Article • Journal of Antimicrobial Chemotherapy, September 2021, Oxford University Press (OUP)

    Lee Fairlie

  75. Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial

    Article • Clinical Trials, September 2021, SAGE Publications

    Lee Fairlie

  76. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

    Article • The Lancet HIV, September 2021, Elsevier

    Lee Fairlie

  77. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial

    Article • PLOS One, August 2021, PLOS

    Lee Fairlie

  78. Effects of preconception antiretroviral therapy in placenta development and pregnancy outcomes

    Article • AIDS, June 2021, Wolters Kluwer Health

    Lee Fairlie

  79. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2021, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  80. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2021, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  81. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age

    Article • AIDS, April 2021, Wolters Kluwer Health

    Lee Fairlie

  82. Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2021, Wolters Kluwer Health

    Lee Fairlie

  83. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAAC...

    Article • The Lancet, April 2021, Elsevier

    Lee Fairlie

  84. Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review

    Article • PLOS One, March 2021, PLOS

    Lee Fairlie

  85. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV

    Article • March 2021, Springer Science + Business Media

    Lee Fairlie

  86. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  87. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

    Article • The Lancet, March 2021, Elsevier

    Lee Fairlie

  88. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

    Article • February 2021, Cold Spring Harbor Laboratory Press

    Lee Fairlie

  89. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa

    Article • AIDS, February 2021, Wolters Kluwer Health

    Lee Fairlie

  90. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

    Article • The Lancet, January 2021, Elsevier

    Lee Fairlie

  91. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Lee Fairlie

  92. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3...

    Article • The Lancet HIV, October 2020, Elsevier

    Lee Fairlie

  93. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial

    Article • The Lancet Infectious Diseases, July 2020, Elsevier

    Lee Fairlie

  94. Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy

    Article • Clinical Infectious Diseases, June 2020, Oxford University Press (OUP)

    Lee Fairlie

  95. Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission

    Article • PLOS One, May 2020, PLOS

    Lee Fairlie

  96. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

    Article • Journal of the Pediatric Infectious Diseases Society, May 2020, Oxford University Press (OUP)

    Lee Fairlie

  97. COVID-19 in Africa: care and protection for frontline healthcare workers

    Article • Globalization and Health, May 2020, Springer Science + Business Media

    Minh Pham, Lee Fairlie

  98. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir

    Article • Antimicrobial Agents and Chemotherapy, April 2020, ASM Journals

    Lee Fairlie

  99. Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006–2017

    Article • The Pediatric Infectious Disease Journal, February 2020, Wolters Kluwer Health

    Lee Fairlie

  100. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes—A randomized clinical trial

    Article • PLOS One, January 2020, PLOS

    Lee Fairlie

  101. African Multi-Site 2-Year Neuropsychological Study of School-Age Children Perinatally Infected, Exposed, and Unexposed to Human Immunodeficiency Virus

    Article • Clinical Infectious Diseases, December 2019, Oxford University Press (OUP)

    Lee Fairlie

  102. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination

    Article • AIDS, December 2019, Wolters Kluwer Health

    Jeffrey S. A. Stringer, Lee Fairlie

  103. Neurodevelopmental delay: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

    Article • Vaccine, December 2019, Elsevier

    Lee Fairlie

  104. Current perspectives on paediatric HIV management from the Mexico International Aids Society Conference, 2019

    Article • Southern African Journal of HIV Medicine, October 2019, AOSIS Open Journals

    Lee Fairlie

  105. Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

    Article • Journal of the International AIDS Society, September 2019, Wiley

    Lee Fairlie

  106. Association between caregiver depression symptoms and child executive functioning. Results from an observational study carried out in four sub-Saharan countries

    Article • AIDS Care, August 2019, Taylor & Francis

    Lee Fairlie , Bonnie Zimmer

  107. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2019, New England Journal of Medicine (NEJM/MMS)

    Lee Fairlie

  108. Why South Africa urgently needs to support the development of pregnancy exposure registries

    Article • South African Medical Journal, April 2019, Health and Medical Publishing Group

    Lee Fairlie

  109. What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies

    Article • The Pediatric Infectious Disease Journal, April 2019, Wolters Kluwer Health

    Lee Fairlie

  110. African Multi-Site Two-Year Longitudinal Study of Neurocognition in HIV Infected/Affected Children

    Article • SSRN Electronic Journal, January 2019, Elsevier

    Lee Fairlie

  111. 287: Diagnostic accuracy of clinical newborn assessment versus ultrasound to define preterm birth: the PROMISE trial

    Article • American Journal of Obstetrics and Gynecology, January 2019, Elsevier

    Lee Fairlie

  112. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)

    Article • Trials, December 2018, Springer Science + Business Media

    Lee Fairlie

  113. Mortality and losses to follow‐up among adolescents living with HIV in the IeDEA global cohort collaboration

    Article • Journal of the International AIDS Society, December 2018, Wiley

    Lee Fairlie

  114. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial

    Article • HIV Clinical Trials, November 2018, Taylor & Francis

    Gerhard Theron, Dr Teacler Gamuchirai Nematadzira, Lee Fairlie

  115. Lamivudine monotherapy as a holding regimen for HIV-positive children

    Article • PLOS One, October 2018, PLOS

    Lee Fairlie

  116. Building capacity in neurodevelopment assessment of children in sub-Saharan Africa: A quality assurance model to implement standardized neurodevelopment testing

    Article • Child Neuropsychology, August 2018, Taylor & Francis

    Lee Fairlie

  117. HIV retesting in pregnant women in South Africa: Outcomes of a quality improvement project targeting health systems’ weaknesses

    Article • Southern African Journal of HIV Medicine, July 2018, AOSIS Open Journals

    Lee Fairlie

  118. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis

    Article • PLoS Medicine, July 2018, PLOS

    Dr. Anthony J. Garcia-Prats, Lee Fairlie

  119. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa

    Article • Medicine, July 2018, Wolters Kluwer Health

    Lee Fairlie

  120. Validity of Neuropsychological Testing in Young African Children Affected by HIV

    Article • Journal of Pediatric Infectious Diseases, March 2018, Mathematical Modelling and Numerical Simulation with Applications

    Lee Fairlie

  121. Thank you from HMPG and the editors

    Article • South African Medical Journal, November 2017, Health and Medical Publishing Group

    Professor Rajendra Bhimma, Lee Fairlie

  122. Lamivudine monotherapy in children and adolescents: The devil is in the detail

    Article • South African Medical Journal, November 2017, Health and Medical Publishing Group

    Lee Fairlie

  123. Neuropsychological performance in African children with HIV enrolled in a multi-site anti-retroviral clinical trial

    Article • AIDS, November 2017, Wolters Kluwer Health

    Lee Fairlie

  124. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial

    Article • PLOS One, June 2017, PLOS

    Lee Fairlie

  125. The interaction between equipoise and logistics in clinical trials: A case study

    Article • Clinical Trials, January 2017, SAGE Publications

    Meredith Warshaw, Lee Fairlie

  126. Cutting the cost of South African antiretroviral therapy using newer, safer drugs

    Article • South African Medical Journal, December 2016, Health and Medical Publishing Group

    Lee Fairlie

  127. Cutting the cost of South African antiretroviral therapy using newer, safer drugs

    Article • South African Medical Journal, December 2016, Health and Medical Publishing Group

    Lee Fairlie

  128. The Challenge of and Opportunities for Transitioning and Maintaining a Continuum of Care Among Adolescents and Young Adults Living with HIV in Resource Limited Settings

    Article • Current Tropical Medicine Reports, October 2016, Springer Science + Business Media

    Lee Fairlie

  129. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial

    Article • Clinical Infectious Diseases, July 2016, Oxford University Press (OUP)

    Lee Fairlie

  130. Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa

    Article • PLOS One, January 2016, PLOS

    Lee Fairlie

  131. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States

    Article • AIDS, October 2015, Wolters Kluwer Health

    Lee Fairlie

  132. Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients

    Article • South African Medical Journal, September 2015, Health and Medical Publishing Group

    Lee Fairlie

  133. Time to implement 9-month infant HIV testing in South Africa

    Article • South African Medical Journal, September 2015, Health and Medical Publishing Group

    Lee Fairlie

  134. Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004–2012

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, August 2015, Wolters Kluwer Health

    Lee Fairlie

  135. Paradoxical tuberculosis‐associated immune reconstitution inflammatory syndrome in children

    Article • Pediatric Pulmonology, June 2015, Wiley

    Lee Fairlie

  136. HIV and adolescents: focus on young key populations

    Article • Journal of the International AIDS Society, February 2015, Wiley

    Lee Fairlie

  137. Providing comprehensive health services for young key populations: needs, barriers and gaps

    Article • Journal of the International AIDS Society, February 2015, Wiley

    Lee Fairlie

  138. Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa

    Article • The Pediatric Infectious Disease Journal, February 2015, Wolters Kluwer Health

    Lee Fairlie

  139. Focus on adolescents with HIV and AIDS

    Article • South African Medical Journal, November 2014, Health and Medical Publishing Group

    Lee Fairlie

  140. Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa

    Article • The International Journal of Tuberculosis and Lung Disease, June 2014, International Union Against Tuberculosis and Lung Disease

    Lee Fairlie

  141. Evaluation of Parent-Child Pairs on Antiretroviral Therapy in Separate Adult and Pediatric Clinics

    Article • Journal of the International Association of Providers of AIDS Care (JIAPAC), October 2013, SAGE Publications

    Lee Fairlie

  142. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa

    Article • AIDS, March 2013, Wolters Kluwer Health

    Lee Fairlie

  143. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa

    Article • Global Health Action, January 2013, Taylor & Francis

    Lee Fairlie

  144. Cost and outcomes of paediatric antiretroviral treatment in South Africa

    Article • AIDS, January 2013, Wolters Kluwer Health

    Lee Fairlie

  145. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents

    Article • Journal of the International AIDS Society, January 2013, Wiley

    Lee Fairlie

  146. Lamivudine Monotherapy as a Holding Strategy in HIV-Infected Children in South Africa

    Article • Journal of AIDS & Clinical Research, January 2013, OMICS Publishing Group

    Lee Fairlie

  147. Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment

    Article • PLOS One, February 2011, PLOS

    Lee Fairlie

  148. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study

    Article • BMC Infectious Diseases, January 2011, Springer Science + Business Media

    Lee Fairlie

  149. Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis

    Article • Antiviral Therapy, April 2010, SAGE Publications

    Lee Fairlie